

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Josee GOLAY et al.

Serial No. (unknown)

Filed herewith

USE OF ANTIBODIES AGAINST CD20
FOR THE TREATMENT OF THE GRAFT
VERSUS HOST DISEASE

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents

Washington, D.C. 20231

Sir:

In compliance with Rules 1.97 and 1.98, and in fulfillment of the duty of disclosure under Rule 1.56, the accompanying documents, copies of which are attached to this statement, are made of record on the enclosed sheet.

A concise explanation of the relevance of these items is that we are advised by our client that these references were cited in International Application PCT/EP00/05212 filed June 7, 2000.

Respectfully submitted,

YOUNG & THOMPSON

By

Benoit Castel

Benoit Castel
Attorney for Applicants
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

December 11, 2001

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
9655

SERIAL NO.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Josee GOLAY et al.

FILING DATE
December 11, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AL	WO 97/45142	12/97	International			yes
	AM	WO 98/42824	10/98	International			yes
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AR	by P. MCLAUGHLIN et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program", <u>JOURNAL OF CLINICAL ONCOLOGY</u> , vol. 16, August 1998, Abstract.
AS	by S. VERZELETTI et al., "Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors", <u>HUMAN GENE THERAPY</u> , vol. 9, no. 15, October 1998, pages 2243-2251.
AT	by Martino INTRONA et al., "Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies", <u>HUMAN GENE THERAPY</u> , vol. 11, no. 4, March 2000, pages 611-620.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.